BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25780283)

  • 1. Targeted therapy in first line treatment of RAS wild type colorectal cancer.
    Formica V; Roselli M
    World J Gastroenterol; 2015 Mar; 21(10):2871-4. PubMed ID: 25780283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
    Hawkes E; Cunningham D
    Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
    Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
    Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.
    De Stefano A; Carlomagno C
    World J Gastroenterol; 2014 Aug; 20(29):9732-43. PubMed ID: 25110411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
    Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
    J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
    Bertagnolli MM
    J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
    [No Abstract]   [Full Text] [Related]  

  • 15. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor in CRC patients in the era of the RAS.
    Yanmaz MT; Demir G; Erdamar S; Keskin S; Aydin MF; Guner SI
    Hepatogastroenterology; 2015; 62(137):40-4. PubMed ID: 25911864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
    Wong R; Cunningham D
    J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
    [No Abstract]   [Full Text] [Related]  

  • 19. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
    Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
    J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
    Russo A; Rizzo S; Bronte G; Silvestris N; Colucci G; Gebbia N; Bazan V; Fulfaro F
    Oncology; 2009; 77 Suppl 1():57-68. PubMed ID: 20130433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.